Pharmacologic properties of proton pump inhibitors

Research output: Contribution to journalArticlepeer-review

47 Scopus citations

Abstract

Since their introduction into clinical practice in the 1980s, proton pump inhibitors (PPIs) have proved to be of enormous value in the management of acid peptic disorders. They have become the treatment of choice for most, if not all, acid-related gastrointestinal disorders, including gastroesophageal reflux disease, peptic ulcer, and Zollinger-Ellison syndrome. With approval of an intravenous formulation, the benefits of PPIs are extended to critically ill patients for whom oral drug administration is often unsuitable. Five PPIs are approved for clinical use in the United States. Although they share a common core structure and mechanism of action, it is important to understand the general pharmacology of these agents and how they differ from histamine 2-receptor antagonists in order to optimize PPI therapy.

Original languageEnglish (US)
Pages (from-to)74S-80S
JournalPharmacotherapy
Volume23
Issue number10 I
DOIs
StatePublished - Oct 1 2003

Fingerprint Dive into the research topics of 'Pharmacologic properties of proton pump inhibitors'. Together they form a unique fingerprint.

Cite this